Agenus Inc. (AGEN) Reports 72% pCR in Phase 2 dMMR Colon Cancer Study

Agenus Inc. reported Phase 2 NEOASIS study results, showing 83% MPR and 72% pCR in 18 dMMR colon cancer patients treated with botensilimab plus balstilimab. The company aims to expand use across tumors, pending further studies and regulatory discussions.

Original reporting
Published Oct 25, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Agenus Inc. (AGEN) Reports 72% pCR in Phase 2 dMMR Colon Cancer Study — source image
Decision brief

The 30-second read

$AGENBullishMed
01

Why it matters

The 72% pCR rate is a strong early signal that could accelerate the company's development timeline and attract partnership interest.

02

Market read

Early trial success is a catalyst for biotech stocks, potentially moving AGEN higher in the short term.

03

What to watch

Regulatory pathway and timeline for pivotal trials remain uncertain.

Relevance 9/10Novelty 9/10Timing: today

Background

Agenus (NASDAQ: AGEN) focuses on immuno‑oncology; the NEOASIS study tests its dual‑checkpoint antibodies botensilimab and balstilimab.

Company-level read

Ticker impact

$AGENBullishMedium confidence
Context

Agenus reported 72% pathological complete response in a Phase 2 neoadjuvant study of dMMR colon cancer.

Expected impact

likely upward pressure as investors price in the efficacy signal

Evidence & confidence

Phase 2 data are material for a biotech; however the trial is small (18 patients) and further validation is needed, tempering the impact.

Market effects

May boost sentiment for dMMR‑targeted immunotherapies and related biotech peers.

Limited to US biotech sector; no broader regional effect.

Modest, confined to investors tracking oncology pipeline news.

Counterpoint

Skeptics may argue the sample size is too small to justify a price rally.

Key entities

  • Agenus Inc.

    Biotech firm developing checkpoint inhibitor therapies.

Related articles

$AGENMedAI 8/10

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.